Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Keratolimbal allograft.

Albert Y Cheung1, Edward J Holland

  • 1aCincinnati Eye Institute bUniversity of Cincinnati, Cincinnati, Ohio, USA.

Current Opinion in Ophthalmology
|April 6, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of allogeneic ocular surface stem cell transplantation.

Frontiers in ophthalmology·2026
Same author

Comparing Global Operating Room Waste Generated From Cataract, Corneal, and Conjunctival Surgeries.

Cornea·2026
Same author

Current Practices, Evolving Techniques, and Immunologic Challenges in Living and Deceased Donor Limbal Stem Cell Transplantation.

American journal of ophthalmology·2026
Same author

Artificial intelligence-assisted diagnosis and subtype differentiation of infectious keratitis.

Eye (London, England)·2026
Same author

Neurotrophic Keratopathy: Current Concepts, Management, and Emerging Treatments.

Cornea·2026
Same author

Tacrolimus-Related Kidney Function Change in Ocular Stem Cell Transplantation.

Cornea·2026
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles

Keratolimbal allograft (KLAL) provides a viable treatment for limbal stem cell deficiency when other options are unavailable. Careful management, including extended immunosuppression, is crucial to prevent graft rejection and ensure successful outcomes in severe cases.

Area of Science:

  • Ophthalmology
  • Regenerative Medicine
  • Transplantation Immunology

Background:

  • Limbal stem cell deficiency (LSCD) causes severe visual impairment.
  • Keratolimbal allograft (KLAL) utilizes donor limbal tissue to restore stem cells.
  • This review focuses on recent advancements in KLAL procedures.

Purpose of the Study:

  • To review the current literature on Keratolimbal allograft (KLAL).
  • To highlight recent findings regarding tissue selection, immunosuppression, and complications.
  • To assess the efficacy and safety of KLAL in treating LSCD.

Main Methods:

  • Review of recent scientific literature on KLAL.
  • Analysis of studies focusing on tissue procurement and preparation.
  • Examination of data on immunosuppressive regimens and adverse events.

Related Experiment Videos

Main Results:

  • Recent studies emphasize optimal tissue selection for KLAL.
  • Immunosuppression protocols and their impact on adverse events are detailed.
  • Postoperative complications, especially immunologic rejection, are a key concern.

Conclusions:

  • KLAL offers a treatment option for LSCD when autografts or related donors are not feasible.
  • Systemic immunosuppression is critical for preventing immunologic rejection after KLAL.
  • Extended immunosuppression duration may be necessary for long-term graft survival.